Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Anti-CD3 drug keeps diabetes at bay

No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to identifying eligible recipients for the treatment.
  1. Elie Dolgin

    1. Somerville, Massachusetts

    View author publications

    You can also search for this author in PubMed  Google Scholar

The first drug to ever slow the progression from pre-diabetes to clinical type 1 diabetes is one step closer to reaching the market.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Biotechnology 37, 1099-1101 (2019)

doi: https://doi.org/10.1038/d41587-019-00025-4

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links